A number of other analysts also recently commented on the company. HC Wainwright reiterated a buy rating on shares of TG Therapeutics in a research report on Tuesday, January 22nd. Jefferies Financial Group restated a buy rating and set a $8.00 target price on shares of TG Therapeutics in a research report on Wednesday, February 6th. B. Riley began coverage on TG Therapeutics in a research report on Tuesday, January 8th. They set a buy rating and a $10.00 target price for the company. Cantor Fitzgerald began coverage on TG Therapeutics in a research report on Friday, March 29th. They set an overweight rating and a $17.00 target price for the company. Finally, ValuEngine downgraded TG Therapeutics from a hold rating to a sell rating in a research report on Thursday, February 28th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $14.07.
Shares of NASDAQ TGTX traded down $0.55 during mid-day trading on Tuesday, reaching $7.56. 1,800,626 shares of the company traded hands, compared to its average volume of 1,406,073. TG Therapeutics has a fifty-two week low of $3.32 and a fifty-two week high of $16.00.
Institutional investors have recently made changes to their positions in the stock. Advisor Group Inc. lifted its holdings in shares of TG Therapeutics by 23.6% in the first quarter. Advisor Group Inc. now owns 7,850 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 1,500 shares in the last quarter. Parametric Portfolio Associates LLC bought a new stake in shares of TG Therapeutics in the first quarter valued at about $117,000. New York State Common Retirement Fund lifted its holdings in shares of TG Therapeutics by 37.2% in the first quarter. New York State Common Retirement Fund now owns 63,100 shares of the biopharmaceutical company’s stock valued at $507,000 after purchasing an additional 17,100 shares in the last quarter. Measured Wealth Private Client Group LLC bought a new stake in TG Therapeutics during the first quarter worth about $291,000. Finally, Raymond James & Associates raised its holdings in TG Therapeutics by 15.6% during the first quarter. Raymond James & Associates now owns 381,437 shares of the biopharmaceutical company’s stock worth $3,067,000 after acquiring an additional 51,418 shares in the last quarter. 55.19% of the stock is owned by institutional investors and hedge funds.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.